{"id":6002,"date":"2024-10-04T08:54:06","date_gmt":"2024-10-04T08:54:06","guid":{"rendered":"https:\/\/presspart.com\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/"},"modified":"2024-11-07T12:14:47","modified_gmt":"2024-11-07T12:14:47","slug":"invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler","status":"publish","type":"post","link":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/","title":{"rendered":"invoX Pharma und H&T Presspart geben strategische Partnerschaft zur Herstellung der Ger\u00e4teunterbaugruppe f\u00fcr die Kommerzialisierung des Softhalers\u00ae bekannt"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

<\/p>\n\n\n\n

L’Arbo\u00e7, Spanien – 4. Oktober 2024 – invoX Pharma Limited (invoX“), ein forschungsorientiertes, weltweit t\u00e4tiges biopharmazeutisches Unternehmen, ist eine neue strategische Zusammenarbeit mit H&T Presspart (einem Gesch\u00e4ftsbereich der Heitkamp & Thumann Group) eingegangen, einem f\u00fchrenden Auftragsentwickler und -hersteller von Komponenten und Ger\u00e4ten zur Verabreichung von Medikamenten.<\/p>\n\n\n\n

Im Rahmen dieser Zusammenarbeit wird H&T Presspart die Ger\u00e4teunterbaugruppe f\u00fcr die Kommerzialisierung des komplexen Soft-Mist-Inhalationsger\u00e4ts (SMI) von invoX, den Softhaler\u00ae, herstellen. Als designierter Industrialisierungs- und Produktionspartner von invoX wird H&T Presspart Komponenten formen und Unterbaugruppen in einem speziellen Reinraum an seinem Standort in Tarragona, Spanien, herstellen.<\/p>\n\n\n\n

Der Softhaler\u00ae ist ein patentrechtlich gesch\u00fctztes Soft-Mist-Inhalationsger\u00e4t der n\u00e4chsten Generation, das eine differenzierte Technologie nutzt, um treibgasfreie Fl\u00fcssigformulierungen in die Lunge zu bringen. Es handelt sich um ein rein mechanisches Ger\u00e4t, das Formulierungen auf Wasserbasis verwendet und keine Treibgase enth\u00e4lt. Das Softhaler\u00ae-Ger\u00e4t wandelt die fl\u00fcssige Formulierung mechanisch in einen ultrafeinen Nebel um, um das Medikament effektiver in die Lunge zu bringen, was zu einer besseren Abgabe in der Lunge und weniger Ablagerungen im Mund oder im hinteren Rachenraum f\u00fchrt.<\/p>\n\n\n\n

invoX Pharma hat eine Reihe von Vereinbarungen f\u00fcr die Entwicklung und Vermarktung von generischen und innovativen Medikamenten-Ger\u00e4te-Kombinationen unter Verwendung des Softhalers\u00ae getroffen.<\/p>\n\n\n\n

\u201eWir freuen uns \u00fcber die Zusammenarbeit mit einem Experten auf dem Gebiet der Herstellung von Medizinproduktkomponenten und der Ger\u00e4temontage\u201c, sagte Ben Toogood, Chief Executive Officer bei invoX. \u201eDiese Partnerschaft wird uns die M\u00f6glichkeit geben, unser Ger\u00e4t im kommerziellen Ma\u00dfstab herzustellen, was ein wichtiger Schritt in der Zusammenarbeit mit unseren Entwicklungspartnern ist, um den Softhaler\u00ae auf den Markt zu bringen. Wir konzentrieren uns darauf, den Softhaler Patienten mit Atemwegserkrankungen zur Verf\u00fcgung zu stellen, damit sie von den Medikamenten profitieren k\u00f6nnen, die durch unser Ger\u00e4t der n\u00e4chsten Generation verabreicht werden.\u201c<\/p>\n\n\n\n

Christian Kr\u00e4tzig, President H&T Presspart, kommentierte: \u201eDiese Partnerschaft unterstreicht unser strategisches Engagement, Kunden bei der Kommerzialisierung von hochkomplexen Medikamenten-Ger\u00e4te-Kombinationen zu unterst\u00fctzen. Als f\u00fchrender Entwickler und Hersteller von Medikamentenverabreichungsger\u00e4ten und mit unserer Expertise im Inhalationsmarkt freuen wir uns sehr \u00fcber die Partnerschaft mit invoX, um Patienten weltweit SMIs der n\u00e4chsten Generation zur Verf\u00fcgung zu stellen.\u201c<\/p>\n\n\n\n

\u00dcber invoX Pharma<\/strong><\/p>\n\n\n\n

invoX Pharma ist ein forschungsorientiertes, globales biopharmazeutisches Unternehmen, das Technologieplattformen der n\u00e4chsten Generation einsetzt, um innovative Medikamente zu entdecken und zu entwickeln, die das Leben von Menschen auf der ganzen Welt ver\u00e4ndern k\u00f6nnen. Das Unternehmen m\u00f6chte das Leben der Menschen verbessern, indem es ihnen Zugang zu innovativen Medikamenten verschafft, die ihren ungedeckten Gesundheitsbedarf decken. Das im M\u00e4rz 2021 gegr\u00fcndete Unternehmen invoX konzentriert sich auf Onkologie und Atemwegstherapeutika und ist in den Bereichen Forschung, klinische Entwicklung und Gesch\u00e4ftsentwicklung in Gro\u00dfbritannien, der EU und den USA t\u00e4tig. F\u00fcr weitere Informationen \u00fcber invoX Pharma besuchen Sie bitte: https:\/\/invoxpharma.com\/<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

L’Arbo\u00e7, Spanien – 4. Oktober 2024 – invoX Pharma Limited (invoX“), ein forschungsorientiertes, weltweit t\u00e4tiges biopharmazeutisches Unternehmen, ist eine neue strategische Zusammenarbeit mit H&T Presspart (einem Gesch\u00e4ftsbereich der Heitkamp & Thumann Group)…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[42,24],"tags":[],"class_list":["post-6002","post","type-post","status-publish","format-standard","hentry","category-products-and-services-de","category-company-news-de"],"acf":[],"yoast_head":"\ninvoX Pharma and H&T Presspart Announce Strategic Partnership<\/title>\n<meta name=\"description\" content=\"H&T Presspart will manufacture the device sub-assembly for the commercialisation of invoX\u2019s complex soft mist inhalation (SMI) device, the Softhaler\u00ae. As invoX\u2019s designated industrialisation and manufacturing partner, H&T Presspart will mould components and produce sub-assemblies in a dedicated clean room at their site in Tarragona, Spain.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"invoX Pharma and H&T Presspart Announce Strategic Partnership\" \/>\n<meta property=\"og:description\" content=\"H&T Presspart will manufacture the device sub-assembly for the commercialisation of invoX\u2019s complex soft mist inhalation (SMI) device, the Softhaler\u00ae. As invoX\u2019s designated industrialisation and manufacturing partner, H&T Presspart will mould components and produce sub-assemblies in a dedicated clean room at their site in Tarragona, Spain.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/\" \/>\n<meta property=\"og:site_name\" content=\"H&T Presspart\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-04T08:54:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-07T12:14:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/presspart.com\/wp-content\/uploads\/2024\/10\/Website-News-Heads-1024x443.png\" \/>\n<meta name=\"author\" content=\"presspart\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"presspart\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/\"},\"author\":{\"name\":\"presspart\",\"@id\":\"https:\/\/presspart.com\/de\/#\/schema\/person\/ea6faba4b50e03fce829becbe473e66f\"},\"headline\":\"invoX Pharma und H&T Presspart geben strategische Partnerschaft zur Herstellung der Ger\u00e4teunterbaugruppe f\u00fcr die Kommerzialisierung des Softhalers\u00ae bekannt\",\"datePublished\":\"2024-10-04T08:54:06+00:00\",\"dateModified\":\"2024-11-07T12:14:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/\"},\"wordCount\":507,\"image\":{\"@id\":\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/presspart.com\/wp-content\/uploads\/2024\/10\/Website-News-Heads-1024x443.png\",\"articleSection\":[\"Produkte und Dienstleistungen\",\"Unternehmensnachrichten\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/\",\"url\":\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/\",\"name\":\"invoX Pharma and H&T Presspart Announce Strategic Partnership\",\"isPartOf\":{\"@id\":\"https:\/\/presspart.com\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/presspart.com\/wp-content\/uploads\/2024\/10\/Website-News-Heads-1024x443.png\",\"datePublished\":\"2024-10-04T08:54:06+00:00\",\"dateModified\":\"2024-11-07T12:14:47+00:00\",\"author\":{\"@id\":\"https:\/\/presspart.com\/de\/#\/schema\/person\/ea6faba4b50e03fce829becbe473e66f\"},\"description\":\"H&T Presspart will manufacture the device sub-assembly for the commercialisation of invoX\u2019s complex soft mist inhalation (SMI) device, the Softhaler\u00ae. As invoX\u2019s designated industrialisation and manufacturing partner, H&T Presspart will mould components and produce sub-assemblies in a dedicated clean room at their site in Tarragona, Spain.\",\"breadcrumb\":{\"@id\":\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#primaryimage\",\"url\":\"https:\/\/presspart.com\/wp-content\/uploads\/2024\/10\/Website-News-Heads-1024x443.png\",\"contentUrl\":\"https:\/\/presspart.com\/wp-content\/uploads\/2024\/10\/Website-News-Heads-1024x443.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/presspart.com\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"invoX Pharma und H&T Presspart geben strategische Partnerschaft zur Herstellung der Ger\u00e4teunterbaugruppe f\u00fcr die Kommerzialisierung des Softhalers\u00ae bekannt\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/presspart.com\/de\/#website\",\"url\":\"https:\/\/presspart.com\/de\/\",\"name\":\"H&T Presspart\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/presspart.com\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/presspart.com\/de\/#\/schema\/person\/ea6faba4b50e03fce829becbe473e66f\",\"name\":\"presspart\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/presspart.com\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f132ba1b1a5a3d6f3cb6529cef071eedff6082ffed6f37fb7fbbf8dde5dedb6e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f132ba1b1a5a3d6f3cb6529cef071eedff6082ffed6f37fb7fbbf8dde5dedb6e?s=96&d=mm&r=g\",\"caption\":\"presspart\"},\"sameAs\":[\"http:\/\/presspart.local\"],\"url\":\"https:\/\/presspart.com\/de\/author\/presspart\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"invoX Pharma and H&T Presspart Announce Strategic Partnership","description":"H&T Presspart will manufacture the device sub-assembly for the commercialisation of invoX\u2019s complex soft mist inhalation (SMI) device, the Softhaler\u00ae. As invoX\u2019s designated industrialisation and manufacturing partner, H&T Presspart will mould components and produce sub-assemblies in a dedicated clean room at their site in Tarragona, Spain.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/","og_locale":"de_DE","og_type":"article","og_title":"invoX Pharma and H&T Presspart Announce Strategic Partnership","og_description":"H&T Presspart will manufacture the device sub-assembly for the commercialisation of invoX\u2019s complex soft mist inhalation (SMI) device, the Softhaler\u00ae. As invoX\u2019s designated industrialisation and manufacturing partner, H&T Presspart will mould components and produce sub-assemblies in a dedicated clean room at their site in Tarragona, Spain.","og_url":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/","og_site_name":"H&T Presspart","article_published_time":"2024-10-04T08:54:06+00:00","article_modified_time":"2024-11-07T12:14:47+00:00","og_image":[{"url":"https:\/\/presspart.com\/wp-content\/uploads\/2024\/10\/Website-News-Heads-1024x443.png","type":"","width":"","height":""}],"author":"presspart","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"presspart","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#article","isPartOf":{"@id":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/"},"author":{"name":"presspart","@id":"https:\/\/presspart.com\/de\/#\/schema\/person\/ea6faba4b50e03fce829becbe473e66f"},"headline":"invoX Pharma und H&T Presspart geben strategische Partnerschaft zur Herstellung der Ger\u00e4teunterbaugruppe f\u00fcr die Kommerzialisierung des Softhalers\u00ae bekannt","datePublished":"2024-10-04T08:54:06+00:00","dateModified":"2024-11-07T12:14:47+00:00","mainEntityOfPage":{"@id":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/"},"wordCount":507,"image":{"@id":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#primaryimage"},"thumbnailUrl":"https:\/\/presspart.com\/wp-content\/uploads\/2024\/10\/Website-News-Heads-1024x443.png","articleSection":["Produkte und Dienstleistungen","Unternehmensnachrichten"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/","url":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/","name":"invoX Pharma and H&T Presspart Announce Strategic Partnership","isPartOf":{"@id":"https:\/\/presspart.com\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#primaryimage"},"image":{"@id":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#primaryimage"},"thumbnailUrl":"https:\/\/presspart.com\/wp-content\/uploads\/2024\/10\/Website-News-Heads-1024x443.png","datePublished":"2024-10-04T08:54:06+00:00","dateModified":"2024-11-07T12:14:47+00:00","author":{"@id":"https:\/\/presspart.com\/de\/#\/schema\/person\/ea6faba4b50e03fce829becbe473e66f"},"description":"H&T Presspart will manufacture the device sub-assembly for the commercialisation of invoX\u2019s complex soft mist inhalation (SMI) device, the Softhaler\u00ae. As invoX\u2019s designated industrialisation and manufacturing partner, H&T Presspart will mould components and produce sub-assemblies in a dedicated clean room at their site in Tarragona, Spain.","breadcrumb":{"@id":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#primaryimage","url":"https:\/\/presspart.com\/wp-content\/uploads\/2024\/10\/Website-News-Heads-1024x443.png","contentUrl":"https:\/\/presspart.com\/wp-content\/uploads\/2024\/10\/Website-News-Heads-1024x443.png"},{"@type":"BreadcrumbList","@id":"https:\/\/presspart.com\/de\/invox-pharma-and-ht-presspart-announce-strategic-partnership-to-manufacture-the-device-sub-assembly-for-commercialisation-of-the-softhaler\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/presspart.com\/de\/"},{"@type":"ListItem","position":2,"name":"invoX Pharma und H&T Presspart geben strategische Partnerschaft zur Herstellung der Ger\u00e4teunterbaugruppe f\u00fcr die Kommerzialisierung des Softhalers\u00ae bekannt"}]},{"@type":"WebSite","@id":"https:\/\/presspart.com\/de\/#website","url":"https:\/\/presspart.com\/de\/","name":"H&T Presspart","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/presspart.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/presspart.com\/de\/#\/schema\/person\/ea6faba4b50e03fce829becbe473e66f","name":"presspart","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/presspart.com\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f132ba1b1a5a3d6f3cb6529cef071eedff6082ffed6f37fb7fbbf8dde5dedb6e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f132ba1b1a5a3d6f3cb6529cef071eedff6082ffed6f37fb7fbbf8dde5dedb6e?s=96&d=mm&r=g","caption":"presspart"},"sameAs":["http:\/\/presspart.local"],"url":"https:\/\/presspart.com\/de\/author\/presspart\/"}]}},"_links":{"self":[{"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/posts\/6002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/comments?post=6002"}],"version-history":[{"count":2,"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/posts\/6002\/revisions"}],"predecessor-version":[{"id":6019,"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/posts\/6002\/revisions\/6019"}],"wp:attachment":[{"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/media?parent=6002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/categories?post=6002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/tags?post=6002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}